ID   P1.HTR.TK-
AC   CVCL_4266
SY   P1.HTR.tk-; P1.HTR1.tk-; P1.B5.4.8.12.16.2.1
DR   CLO; CLO_0008290
DR   CLDB; cl3804
DR   ECACC; 87121103
DR   Wikidata; Q54937217
RX   PubMed=3929396;
CC   Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC   Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; Q9QNF7; Human herpesvirus 1 TK.
CC   Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21632; Mouse mast cell neoplasm
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4265 ! P1.HTR
SX   Male
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 13
//
RX   PubMed=3929396; DOI=10.1007/BF01534840;
RA   Van Pel A., De Plaen E., Boon T.;
RT   "Selection of highly transfectable variant from mouse mastocytoma
RT   P815.";
RL   Somat. Cell Mol. Genet. 11:467-475(1985).
//